We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Juno Therapeutics (JUNO) in Focus: Stock Gains 9.5%
Juno Therapeutics Inc. was a big mover last session, as the company saw its shares rise roughly 10% on the day. The stock moved up after the biopharmaceutical company got the nod from regulators to resume clinical trials of an experimental leukemia treatment. This led to solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 25.9% in the past one-month time frame.
None of the estimates for this company were revised over the past 30 days. The Zacks Consensus Estimate however moved down over the same time frame, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts.
Juno Therapeutics has a Zacks Rank #4 (Sell), while its Earnings ESP is negative.
JUNO THERAPEUTC Price
JUNO THERAPEUTC Price | JUNO THERAPEUTC Quote
However, a better-ranked stock in the Med-Biomed/Gene space is CytRx Corporation , sporting a Zacks Rank #1 (Strong Buy).
Is JUNO going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>